Mixed states are common and severe manifestations of bipolar disorder, with limited data on
the differential efficacy of treatments on depressive and manic symptoms. This study
assessed the effectiveness of open-label adjunctive risperidone in achieving sustained
effectiveness in patients with mixed mania, with a specific focus on the differential benefits
on manic and depressive symptomatology. Forty patients with bipolar disorder I, currently in
a mixed manic episode, were treated with adjunctive risperidone. Behavioral measures at …